Hair Repigmentation Reported With Baricitinib in Canities Subita
-
By
-
Andrea Surnit
-
June 15, 2026
-
4 min
By
Andrea Surnit
June 15, 2026
Phase 3 data showed high skin clearance rates and adverse event rates similar to placebo through week 16 with once-daily icotrokinra.
March 18, 2026
New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.
May 18, 2026